Modena University Hospital Closes Lot 19 Dermal Substitutes Tender

Standfirst

A healthcare procurement led by Azienda Ospedaliera-Universitaria di Modena covered the supply of medical devices for breast reconstructive surgery through a 22-lot procedure involving healthcare organisations in the Emilia Nord area. The procurement had an estimated overall value of €29.79 million excluding VAT and a planned contract duration of three years. However, the published result for Lot 19, covering dermal substitutes, confirms that no winner was selected. The competition was closed following a change in the buyer's needs, with the notice recording zero tenders received for the lot.

Introduction

A result notice published in the Official Journal of the European Union (OJ S 212/2026) provides an update on an Italian public procurement for medical devices used in breast reconstructive surgery. The procedure, identified as 756605-2026, was organised by Azienda Ospedaliera-Universitaria di Modena as the lead purchasing organisation for a group of healthcare entities in the Emilia Nord area.

The procurement was designed to cover 22 separate lots of medical devices, including breast implants, breast expanders and matrices. The participating healthcare organisations named in the procedure description were AOU Modena, AUSL Modena, AUSL Reggio Emilia, AOU Parma, AUSL Piacenza and Ospedale Sassuolo S.p.A.

The overall estimated procurement value was €29,792,205 excluding VAT. The contract description specified a three-year duration. The result information in the notice, however, focuses on LOT-0019 – Sostituti Dermici (Dermal Substitutes). For this lot, the authority reported that no winner was chosen and the competition was closed because of a change in its needs.

The notice is therefore a procurement result update, but it does not announce a successful supplier or a contract award for Lot 19.

Why This Contract Matters

The procurement is relevant to suppliers of medical devices for reconstructive breast surgery, particularly manufacturers and distributors of surgical implants, breast expanders and dermal substitute products. It represents a coordinated purchasing exercise involving several healthcare organisations in the Emilia Nord area rather than a procurement described for a single hospital alone.

The use of 22 lots indicates that the purchasing requirement was divided into separate product or supply categories. Such a structure can allow healthcare buyers to define requirements and assess offers for different product groups independently. For suppliers, the lot structure is important because an opportunity may be relevant to a specific product portfolio rather than the entire procurement.

At the same time, the Lot 19 result demonstrates why suppliers should monitor the outcome of individual lots rather than relying only on the overall procurement title or estimated value. Although the overall procedure had a substantial estimated value, the published result for dermal substitutes did not lead to a supplier selection.

Contract Timeline

The TED notice provides the following publication and procedure information:

• Notice dispatch date: 30 October 2026.
• TED publication date: 2 November 2026.
• Official Journal issue: OJ S 212/2026.
• Procedure type: Open procedure.
• Result for Lot 19: No winner chosen; competition closed.
• Reason for non-award: Decision of the buyer because of a change in needs.

The result notice does not provide a contract signature date or a supplier commencement date for Lot 19 because no winner was selected for that lot.

Contract Overview

The procurement was titled “Fornitura in 22 Lotti di DM per chirurgia ricostruttiva mammaria”, referring to the supply of medical devices for breast reconstructive surgery in 22 separate lots.

The procedure description identifies the products as prostheses, breast expanders and matrices. The procurement was conducted as an open procedure under Directive 2014/24/EU. Azienda Ospedaliera-Universitaria di Modena acted as the lead organisation for the joint purchasing arrangement involving the named healthcare entities in Emilia Nord and Ospedale Sassuolo S.p.A.

The main CPV classification was 33184100 – Surgical implants. The place of performance identified in the notice was Modena, Italy, under NUTS code ITH54.

The overall estimated value excluding VAT and the maximum value of the framework agreement were both stated as €29,792,205. The procedure description specified a three-year contract duration. For Lot 19, the estimated value excluding VAT was €3,951,675.

Key Contract Details

Project Scope

The overall procurement concerned medical devices for breast reconstructive surgery. The procedure description identifies three broad product categories: prostheses, breast expanders and matrices. These products were included in a procurement divided into 22 distinct lots.

The result information available for this notice identifies Lot 19 as “Sostituti Dermici”, or dermal substitutes. The lot's description repeats this product category and assigns it the main CPV code 33184100, Surgical implants.

The notice records an estimated value of €3,951,675 excluding VAT for Lot 19. However, the result confirms that the authority did not select a winner and closed the competition because its requirements had changed.

The published result does not provide a detailed technical specification, product quantities, delivery schedule or individual hospital allocation for the dermal substitutes lot. These details should not be inferred from the general procurement description.

About the Contracting Authority

Azienda Ospedaliera-Universitaria di Modena was identified as the buyer and lead organisation for the joint purchasing procedure. The authority is classified in the notice as a body governed by public law and controlled by a regional authority. Its main activity is health.

The buyer's contact point was Chiara Malagola. The notice lists the following contact information:

• Organisation: Azienda Ospedaliera-Universitaria di Modena
• Location: Modena, Italy
• Postcode: 41100
• Email: acquisti.segreteria@pec.aou.mo.it
• Telephone: 0594222390
• Website: www.aou.mo.it

The joint purchasing arrangement described in the procedure included AOU Modena, AUSL Modena, AUSL Reggio Emilia, AOU Parma, AUSL Piacenza and Ospedale Sassuolo S.p.A. The notice identifies AOU Modena as the lead organisation.

About the Organisations Involved

The procurement brought together healthcare organisations from the Emilia Nord area. The entities named in the procedure description were:

• Azienda Ospedaliera-Universitaria di Modena (AOU Modena): Lead purchasing organisation and the buyer identified in the TED notice.
• AUSL Modena: A participating healthcare organisation in the joint purchasing arrangement.
• AUSL Reggio Emilia: A participating healthcare organisation.
• AOU Parma: A participating university hospital organisation.
• AUSL Piacenza: A participating healthcare organisation.
• Ospedale Sassuolo S.p.A.: Also included in the procurement description.

The result notice also identifies TAR Emilia Romagna – Bologna as the review organisation and ANAC – Autorità Nazionale Anticorruzione as the procurement service provider. The notice does not identify a successful supplier for Lot 19.

Procurement Analysis

The procurement was conducted through an open procedure under Directive 2014/24/EU. The result notice identifies the award criterion as the most economically advantageous tender, with a quality-based criterion description. It also records the following scoring split for Lot 19:

• Economic score: 19 points.
• Technical score: 81 points.

This weighting gives technical considerations a substantially higher share of the stated evaluation score than price. For medical device suppliers, such a structure indicates that technical aspects were intended to play a major role in the evaluation. The notice does not provide the detailed technical sub-criteria or their individual scoring rules.

Despite the stated evaluation approach, the result for Lot 19 was not an award. The buyer reported that no winner was chosen and that the competition was closed following a change in needs. The notice records zero tenders, including zero electronically submitted tenders, for this lot.

The procurement technique specified for Lot 19 was a framework agreement without reopening of competition. The notice also states that no dynamic purchasing system was used.

Additional Procurement Facts

Several additional details in the result notice are relevant to suppliers reviewing the procurement:

• EU funding: The procurement project was not financed with EU funds.
• GPA coverage: Lot 19 was not covered by the Government Procurement Agreement.
• Procedure acceleration: The procedure was not accelerated.
• Submission outcome: The notice records zero tenders for Lot 19.
• Framework arrangement: Framework agreement without reopening of competition.
• Dynamic purchasing system: No DPS was used.
• Review body: TAR Emilia Romagna – Bologna.
• Review deadline information: The notice directs readers to the tender specifications (“Vedi capitolato”).

The notice does not state a successful tenderer's name, a winning tender price or a contract conclusion date for Lot 19 because the competition was closed without selecting a winner.

Market and Industry Perspective

The procurement is relevant to the medical device market serving reconstructive breast surgery. Its product scope included prostheses, breast expanders and matrices, while the result details for Lot 19 concerned dermal substitutes. Suppliers active in these categories may monitor similar public procurement notices issued by hospitals and healthcare purchasing organisations.

The joint purchasing arrangement is also a relevant feature. By bringing together multiple healthcare entities, the procedure established a common purchasing exercise for the Emilia Nord area. For suppliers, this means that procurement notices organised by a lead hospital may represent requirements associated with more than one healthcare institution.

However, the Lot 19 outcome should be interpreted narrowly. The result notice does not establish that all 22 lots were cancelled or that the wider procurement failed. It records the non-award decision for the specific lot identified in the result section.

Economic Significance

The estimated value of the overall procurement was €29,792,205 excluding VAT, while the maximum value of the framework agreement was also stated as €29,792,205. The estimated value assigned to Lot 19 was €3,951,675 excluding VAT.

These figures indicate the financial scale of the planned procurement, but they should not be described as awarded contract expenditure. The result for Lot 19 confirms that no supplier was selected and no winning contract value was reported for that lot.

The notice also states that the procurement was not financed with EU funds. It does not provide a breakdown of the estimated overall value among the participating healthcare organisations or detailed quantities for the products in Lot 19.

Future Procurement Opportunities

The closure of Lot 19 without an award does not, by itself, establish whether the buyer will issue a revised tender, modify its requirements or pursue another purchasing route. The result notice gives only the reason for the non-award decision: a change in the buyer's needs.

Suppliers of dermal substitutes and related reconstructive surgery devices should therefore monitor subsequent procurement publications from Azienda Ospedaliera-Universitaria di Modena and the participating healthcare organisations. Any future opportunity should be assessed using its own notice, specifications, product requirements and submission conditions.

Businesses can also monitor new Italian tender notices and contract outcomes through Italytenders's tender listings and contract award notices.

Opportunities for Suppliers

Although Lot 19 did not result in a contract award, the procurement provides useful information for suppliers operating in the medical device sector. Companies may use the notice to understand the product categories and purchasing structure considered by the participating healthcare organisations.

Relevant suppliers may include:

• Manufacturers and distributors of dermal substitutes.
• Suppliers of breast implants and prostheses.
• Manufacturers of breast expanders.
• Medical device companies supplying products for reconstructive surgery.
• Distributors and authorised representatives serving Italian hospitals and healthcare organisations.

For future competitions, suppliers should review technical specifications carefully and prepare product documentation that addresses the buyer's stated requirements. The 19-point economic and 81-point technical scoring split recorded for Lot 19 may also be useful context, although any future procedure could use different criteria.

Companies seeking to follow procurement opportunities in Italy can register with Italytenders or log in to access the platform's tender information.

What Businesses Should Watch

Medical device suppliers monitoring this procurement should pay attention to several points:

• Any revised notice: Watch for a new or amended procurement relating to dermal substitutes or breast reconstructive surgery devices.
• Changes in technical requirements: The stated reason for closing Lot 19 was a change in the buyer's needs. Future specifications may therefore differ from the original requirements.
• Lot-level results: The result information in this notice concerns Lot 19. Suppliers should check the outcomes of other lots separately rather than assuming that the same result applies to the entire 22-lot procedure.
• Evaluation criteria: The notice records an economic score of 19 and a technical score of 81 for Lot 19. Detailed evaluation rules should be checked in the relevant procurement documents.
• Review information: The named review organisation is TAR Emilia Romagna – Bologna. The notice refers suppliers to the tender specifications for information about review deadlines.

Italytenders Procurement Intelligence

The result of TED notice 756605-2026 illustrates the importance of monitoring procurement outcomes at lot level. The overall procedure concerned a €29.79 million estimated purchasing programme for medical devices used in breast reconstructive surgery, but the published result for Lot 19 records no successful supplier and no contract award.

For suppliers, distinguishing between an estimated procurement value and an awarded contract value is essential. The €3.95 million estimate for Lot 19 represents the planned value stated in the notice, not confirmed business awarded to a supplier. The zero-tender result and the buyer's decision to close the competition are the key outcome indicators for this lot.

Italytenders provides access to global tender opportunities and procurement award information, helping businesses follow tender publications and compare procurement outcomes. Organisations can use the platform to monitor relevant public procurement activity and identify opportunities that match their product and service categories.

Supplier Takeaways

• TED notice 756605-2026 relates to an Italian procurement for medical devices used in breast reconstructive surgery.
• The overall procedure was divided into 22 lots and had an estimated value of €29,792,205 excluding VAT.
• The result details in this notice concern LOT-0019, covering dermal substitutes.
• Lot 19 had an estimated value of €3,951,675 excluding VAT.
• No winner was selected for Lot 19, and the competition was closed because the buyer's needs had changed.
• The notice records zero tenders received for the lot.
• The stated evaluation split was 19 points for the economic score and 81 points for the technical score.
• Suppliers should monitor the buyer's future publications for any revised or replacement procurement.

Key Takeaways

• Buyer: Azienda Ospedaliera-Universitaria di Modena, acting as the lead organisation.
• Procurement: Supply of medical devices for breast reconstructive surgery through 22 lots.
• Overall estimated value: €29.79 million excluding VAT.
• Lot 19: Dermal substitutes, with an estimated value of €3.95 million excluding VAT.
• Procedure: Open procedure under Directive 2014/24/EU.
• Result: No winner chosen; competition closed due to a change in the buyer's needs.
• Tenders received: Zero for Lot 19.
• Publication: 2 November 2026, OJ S 212/2026.

Conclusion

TED notice 756605-2026 reports the result of an Italian procurement for medical devices used in breast reconstructive surgery. The wider procedure was organised across 22 lots for a group of healthcare organisations in the Emilia Nord area, with an estimated overall value of €29,792,205 excluding VAT.

For Lot 19, covering dermal substitutes, the authority did not select a supplier. The competition was closed because of a change in the buyer's needs, and the notice records no tenders received. The result is therefore a non-award outcome for this specific lot, not confirmation of a contract placed at the estimated value.

Suppliers active in breast reconstruction and related medical device categories should monitor future notices from the participating healthcare organisations for any revised requirements or new procurement opportunities.

Source

• Official TED notice: 756605-2026 – Italy: Surgical implants
• Contracting authority: Azienda Ospedaliera-Universitaria di Modena
• Review organisation: TAR Emilia Romagna – Bologna
• Publication: Official Journal of the European Union, OJ S 212/2026, 2 November 2026